« Back
Home /
Ciprofloxacin

Ciprofloxacin

Item no.	HY-B0356-5g
Manufacturer	MedChem Express
CASRN	85721-33-1
Amount	5 g
Quantity options	1 g 500 mg 5 g
Category	Food Safety Antibiotics Inhibitors & Compound Libraries Small Molecules
Type	Inhibitors
Specific against	other
Purity	99.96
Citations	[1]Tsai WC, et, al. Ciprofloxacin-mediated cell proliferation inhibition and G2/M cell cycle arrest in rat tendon cells. Arthritis Rheum. 2008 Jun;58(6):1657-63.\|[2]Steenbergen J, et, al. In Vitro and In Vivo Activity of Omadacycline against Two Biothreat Pathogens, Bacillus anthracis and Yersinia pestis. Antimicrob Agents Chemother. 2017 Apr 24;61(5):e02434-16.\|[3]Hamblin KA, et, al. Inhaled Liposomal Ciprofloxacin Protects against a Lethal Infection in a Murine Model of Pneumonic Plague. Front Microbiol. 2017 Feb 6;8:91.\|[4]LeMaire SA, et, al. Effect of Ciprofloxacin on Susceptibility to Aortic Dissection and Rupture in Mice. JAMA Surg. 2018 Sep 1;153(9):e181804. Adv Sci (Weinh). 2020 Jul 21;7(17):2001374. Anal Chim Acta. 2022 Aug 15:1221:340082. Anim Dis. 2021;1(1):26. Antimicrob Agents Chemother. 2025 May 23:e0024925. Appl Biochem Biotechnol. 2025 Aug 23. Appl Microbiol Biotechnol. 2022 Apr;106(7):2689-2702. Arab J Chem. 2024 May, 17, 5, 105745. bioRxiv. 2024 May 10. bioRxiv. 2024 Nov 06. Cardiovasc Toxicol. 2024 Sep;24(9):889-903. Chemosphere. 2019 Jun:225:378-387. Diagn Microbiol Infect Dis. 2025 Nov 4;114(2):117181. EBioMedicine. 2022 Apr;78:103943. Eur J Clin Microbiol Infect Dis. 2025 Sep 29. Front Microbiol. 2022 Feb 16:12:773664. Genome Biol. 2023 Apr 30;24(1):98. Infect Drug Resist. 2025 Oct 4:18:5239-5247. Int J Antimicrob Agents. 2018 Aug;52(2):269-271. iScience. 2023 Oct 7;26(11):108158. J Antimicrob Chemother. 2020 Jul 1;75(7):1850-1858. J Med Chem. 2025 Dec 11;68(23):25274-25289. Microb Pathog. 2024 Jun:191:106666. Microbiol Spectr. 2022 Apr 25:e0251821. Microbiol Spectr. 2022 Feb 23;10(1):e0099121. Microbiol Spectr. 2025 May 19:e0307424. Molecules. 2023 Jun 8;28(12):4628. Nat Cell Biol. 2024 Sep;26(9):1545-1557. Nature. 2024 Aug;632(8027):1137-1144. NPJ Biofilms Microbiomes. 2024 Oct 28;10(1):111. Orebro University. 2024. Patent. US20200101105A1. PLoS Pathog. 2024 Dec 31;20(12):e1012783. Research Square Preprint. 2020 Jun. Vet Microbiol. 2024 May:292:110046. Virulence. 2024 Dec;15(1):2415952. Water Res. 2023 Jul 15:240:120110. Water Res. 2024 Nov 29:271:122885. Water. 2025 Jun 6. ACS Appl Polym Mater. 2023 Aug 29. bioRxiv. 2024 Jan 18. Chem Eng J. 2025 May 1. Anim Dis. 2021;1(1):26. Arch Pharm Res. 2025 Jan;48(1):102-114. bioRxiv. 2024 Feb 9. Nat Commun. 2022 Mar 2;13(1):1116.
Smiles	O=C(C1=CN(C2CC2)C3=C(C=C(F)C(N4CCNCC4)=C3)C1=O)O
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	Bay-09867
Shipping Condition	Room temperature
Available
Manufacturer - Type	Reference compound
Manufacturer - Applications	COVID-19-immunoregulation
Manufacturer - Category	Lead-like compounds; Reference compound / Active compounds; API
Manufacturer - Targets	Antibiotic; Apoptosis; Bacterial; Mitochondrial Metabolism; Reactive Oxygen Species (ROS); Topoisomerase
Manufacturer - HS Code	H315, H319, H335
Shipping Temperature	Room Temperature
Storage Conditions	4°C (Powder, protect from light)
Molecular Weight	331.34
Product Description	Ciprofloxacin (Bay-09867) is a potent, orally active topoisomerase IV inhibitor. Ciprofloxacin induces mitochondrial DNA and nuclear DNA damage and lead to mitochondrial dysfunction, ROS production. Ciprofloxacin has anti-proliferative activity and induces apoptosis. Ciprofloxacin is a fluoroquinolone antibiotic, exhibiting potent antibacterial activity[1][2][3][4].
Manufacturer - Research Area	Cancer; Infection
Solubility	0.1 M HCl : 16.67 mg/mL (ultrasonic; warming; adjust pH to 2 with HCl; heat to 60°C)\|DMSO : 4.86 mg/mL (ultrasonic; warming; adjust pH to 5 with 1 M HCl; heat to 60°C)\|H2O : 6.78 mg/mL (ultrasonic; warming; adjust pH to 3 with 1 M HCl; heat to 60°C)
Manufacturer - Pathway	Anti-infection; Apoptosis; Cell Cycle/DNA Damage; Immunology/Inflammation; Metabolic Enzyme/Protease; NF-κB
Clinical information	Launched
Isoform	Quinolone
UNSPSC Code	12352005
Precautionary	H315, H319, H335

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.